AstraZeneca presents superior progression-free survival for IMFINZI® ( durvalumab) in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress
PACIFIC survival explained: Cancer spread red | EurekAlert!
david vicente baz on Twitter: "Very proud of our contribution to PACIFIC clinical trial. Durvalumab as new standard of care in unresectable stage III non small cell lung cancer after chemoradiotherapy Many
First-line Durvalumab Improves Survival
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study - Clinical Lung Cancer
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Nathan A. Pennell MD, PhD, FASCO on Twitter: "The PACIFIC trial of consolidation durvalumab starting up to 42 days after concurrent chemoradiation for unresectable stage 3 NSCLC is already SOC due to
Gerry Hanna 💙 on Twitter: "PACIFIC study - adjuvant Durvalumab demonstrates a major step change in the management of stage 3 NSCLC with a clear increase in OS #WCLC2018 @IASLC @BTOGORG #radonc @
First-line Durvalumab Improves Survival
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - ScienceDirect
Exploratory 3-year overall survival for patients with unresectable... | Download Scientific Diagram
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
PACIFIC: Durvalumab in Stage III NSCLC - Capsule Summary Slidesets - 2018 WCLC Annual Meeting - Oncology - Clinical Care Options
Durvalumab - Wikipedia
Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity - memoinOncology
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial - The Lancet Oncology
Cancers | Free Full-Text | Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer | HTML
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis - Lung Cancer
IMFINZI® (durvalumab) Efficacy for Unresectable Stage III NSCLC
